Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel^®) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer.

Authors

Hyung-Don Kim, Sungju Kim, Eileen J Shin, Jiyeon Lee, Jiwon Lee, Myungchul Lee, Jeongeun Shin, Min-Hee Ryu

Published in

Journal of gastric cancer. Volume 26. Issue 4. Pages 573-584.

Abstract

Intravenous (IV) paclitaxel is widely used in the treatment of advanced gastric cancer. Liporaxel^® is the first orally administered paclitaxel formulation and demonstrated non-inferiority to paclitaxel administered every 3 weeks in the phase III DREAM trial. As no head-to-head trial has compared Liporaxel^® with the widely used weekly paclitaxel regimen in gastric cancer, this study aimed to compare their relative efficacy.
This study utilized individual patient data from the DREAM trial and aggregate data for the weekly paclitaxel regimen from a systematic literature review. Given the absence of a common comparator, an unanchored matching-adjusted indirect comparison (MAIC) was performed for progression-free survival (PFS) and overall survival (OS) with weighting based on common and extended variables. Primary and sensitivity analyses were performed according to the effective sample size (ESS).
Matching was performed across 5 studies. Despite a reduction in the ESS, baseline patient characteristics remained similarly distributed after matching. In the two studies included in the primary analysis, the adjusted hazard ratios from the unanchored MAIC, based on common variables, were 0.95 (95% confidence interval [CI], 0.72-1.26) and 1.03 (95% CI, 0.81-1.29) for PFS, and 0.94 (95% CI, 0.69-1.28) and 1.06 (95% CI, 0.84-1.34) for OS. The results obtained using the extended variables and sensitivity analyses were consistent with the primary analysis.
The efficacy of Liporaxel^® and the weekly IV paclitaxel regimen were comparable. This finding supports the previously established non-inferiority evidence and suggests Liporaxel^® as a valid treatment option for advanced gastric cancer.

PMID:
42845257
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.